[6-K] Purple Biotech Ltd. American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Purple Biotech Ltd. (PPBT) filed a Form 6-K on 23 June 2025. The sole purpose of the submission is to furnish a press release titled “Purple Biotech Announces Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress.” The press release is included as Exhibit 99.1.

The filing contains no financial statements, earnings figures, or transactional details. It merely places the press release—and all statements therein—into the U.S. public record and incorporates the document by reference into numerous outstanding registration statements (Forms S-8, F-1 and F-3) dating from 2016 through 2024. The Company also confirms that Chief Executive Officer Gil Efron signed the submission on behalf of the registrant.

Because the actual press release text is not included, investors only learn that Purple Biotech believes its CAPTN-3 tri-specific antibody platform demonstrates “significant advantages” and that these data were highlighted at the European Association for Cancer Research (EACR) 2025 Annual Congress. No quantitative efficacy results, clinical-stage milestones, or development timelines are provided in this 6-K.

Positive

• Press release furnished: The Company highlights “significant advantages” of its novel CAPTN-3 tri-specific antibody platform at the EACR 2025 Congress, signalling ongoing R&D progress.

Negative

• None.

Insights

Biotech Analyst

TL;DR: Routine 6-K; furnishes R&D press release without data—incremental disclosure, limited immediate valuation impact.

The filing formally places a marketing-oriented press release into the SEC database. While the headline suggests scientific differentiation of the CAPTN-3 tri-specific antibody platform, the absence of efficacy numbers, trial phase disclosures, or regulatory milestones prevents a robust assessment of materiality. Incorporation into multiple shelf and equity compensation registration statements is typical housekeeping. Unless the underlying press release (not provided here) contains clinically meaningful updates, the 6-K is best viewed as non-material from a financial perspective.

Portfolio Manager

TL;DR: PR-centric filing, no financials; negligible portfolio impact today.

From a capital-markets standpoint, this 6-K neither updates cash runway nor changes the investment thesis. Management simply cross-references the press release into existing shelf registrations, preserving flexibility for future offerings. The mention of “significant advantages” may support sentiment but, without supporting trial data, is insufficient to drive valuation adjustments. I would categorize the disclosure as routine and monitor subsequent clinical readouts for tangible catalysts.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

  

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

For the month of June 2025

Commission File Number: 001-37643

 

PURPLE BIOTECH LTD.

(Translation of registrant’s name into English)

 

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. 

 

Form 20-F ☒    Form 40-F ☐

 

 

 

 

 

 

Purple Biotech

 

On June 23, 2025, Purple Biotech Ltd. (the “Company” or the “Registrant”) issued a press release, “Purple Biotech Announces Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress”, which is attached hereto as Exhibit 99.1.

 

Exhibit	 	 
99.1	 	Press Release issued by Purple Biotech Ltd. on June 23, 2025

 

Incorporation by Reference

 

This Report on Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission on December 27, 2019 (Registration file number 333-235729), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333-238229), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 18, 2020 (Registration file number 333-238481), each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107) and the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on March 23, 2023 (Registration file number 333-270769), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on December 8, 2022 (Registration file number 333-268710), the Registrant’s Registration Statement on Form F-1, as amended, originally filed with the Securities and Exchange Commission on October 30, 2023 (Registration file number 333-275216) and the Registrant’s Registration Statement on Form F-1, filed with the Securities and Exchange Commission on July 22, 2024 (Registration file number 333-280947), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

 

June 23, 2025	PURPLE BIOTECH LTD.
 	 
 	By:	/s/ Gil Efron
 	 	Gil Efron
 	 	Chief Executive Officer

 

 

2

 

 

FAQ

What did Purple Biotech (PPBT) file on June 23 2025?

The company filed a Form 6-K to furnish a press release about its CAPTN-3 tri-specific antibody platform.

Does the 6-K include any financial results or earnings data?

No. The filing contains no financial statements, earnings figures, or guidance.

What is the main subject of the attached Exhibit 99.1?

Exhibit 99.1 is a press release entitled “Purple Biotech Announces Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress.”

Who signed the Form 6-K on behalf of Purple Biotech?

Chief Executive Officer Gil Efron signed the submission.

Are any of Purple Biotech’s registration statements affected by this filing?

Yes. The 6-K is incorporated by reference into multiple outstanding Form S-8, F-1, and F-3 registration statements dating from 2016-2024.